SR1078
(Synonyms: SR 1078;SR-1078) 目录号 : GC16392
SR1078是一种维甲酸受体相关孤儿受体（ROR）RORα和RORγ的激动剂，IC50值均为1-3µM。
Cas No.:1246525-60-9
Sample solution is provided at 25 µL, 10mM.
SR1078 is an agonist of the retinoic acid receptor-related orphan receptors (RORs) RORα and RORγ, with IC50 values of 1-3µM[1]. SR1078 can directly bind to the ligand binding domains of RORα and RORγ, increasing the transcriptional activity of these receptors, thereby stimulating the transcription of RORα/γ target genes[2, 3]. SR1078 can regulate osteoblast metabolism through anti-inflammatory effects[4].
In vitro, SR1078 (2-10µM) treatment of human neuroblastoma SH-SY5Y cells for 24h increased the expression of A2BP1, CYP19A1, NLGN1 and IPTR1 genes in the cells in a dose-dependent manner, with an EC50 range of 3-5μM[5]. SR1078 (1, 5µM) treatment of HepG2 cells increased the expression of p53 protein and induced cell apoptosis[6].
In vivo, SR1078 (20mg/kg) was intraperitoneally injected into mice bearing colorectal cancer cell xenografts, significantly inhibiting the growth of subcutaneous tumors and the metastasis of tumor cells[7].
References:
[1] Wang Y, Kumar N, Nuhant P, et al. Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORα and RORγ[J]. ACS chemical biology, 2010, 5(11): 1029-1034.
[2] Kamenecka T M, Lyda B, Chang M R, et al. Synthetic modulators of the retinoic acid receptor-related orphan receptors[J]. MedChemComm, 2013, 4(5): 764-776.
[3] Nematisouldaragh D, Kirshenbaum E, Uzonna M, et al. The Role of Retinoic-Acid-Related Orphan Receptor (RORs) in Cellular Homeostasis[J]. International Journal of Molecular Sciences, 2024, 25(21): 11340.
[4] Fernandes J, Benderdor M, Shi Q. SR1078, A synthetic ligand of nuclear receptor ror alpha, modulates osteoblast metabolism with anti-inflammatory effects[J]. Osteoarthritis and Cartilage, 2012, 20: S115-S116.
[5] Wang Y, Billon C, Walker J K, et al. Therapeutic effect of a synthetic RORα/γ agonist in an animal model of autism[J]. ACS Chemical Neuroscience, 2016, 7(2): 143-148.
[6] Wang Y, Solt L A, Kojetin D J, et al. Regulation of p53 stability and apoptosis by a ROR agonist[J]. PloS one, 2012, 7(4): e34921.
[7] Wang Y N, Ruan D Y, Wang Z X, et al. Targeting the cholesterol-RORα/γ axis inhibits colorectal cancer progression through degrading c-myc[J]. Oncogene, 2022, 41(49): 5266-5278.
SR1078是一种维甲酸受体相关孤儿受体（ROR）RORα和RORγ的激动剂，IC50值均为1-3µM[1]。SR1078能够直接与RORα和RORγ 的配体结合结构域结合，增加这些受体的转录活性，从而刺激RORα/γ靶基因转录[2, 3]。SR1078能够通过抗炎作用调节成骨细胞代谢[4]。
在体外，SR1078（2-10µM）处理人神经母细胞瘤SH-SY5Y细胞24h，以剂量依赖性方式增加了细胞中A2BP1、CYP19A1、NLGN1和IPTR1基因的表达，EC50范围为3-5μM[5]。SR1078（1, 5µM）处理HepG2细胞，增加了p53蛋白的表达，诱导了细胞凋亡[6]。
在体内，SR1078（20mg/kg）通过腹腔注射治疗结直肠癌细胞异种移植小鼠，显著抑制了小鼠皮下肿瘤的生长，抑制了肿瘤细胞的转移[7]。
| Cell experiment [1]: | |
Cell lines | SH-SY5Y cells |
Preparation Method | SH-SY5Y were treated with SR1078 (2-10µM), and after 24h cells were harvested and cDNA prepared to assess the expression of autism spectrum disorder (ASD)-associated genes by quantitative PCR. |
Reaction Conditions | 2-10µM; 24h |
Applications | SR1078 increases the expression of ASD-associated genes in SH-SY5Y cells. SR1078 treatment increased the expression of A2BP1, CYP19A1, NLGN1, and IPTR1 in a dose-dependent manner with EC50 ranging from 3-5μM. |
| Animal experiment [2]: | |
Animal models | Female BALB/c athymic nude mice |
Preparation Method | To establish the subcutaneous tumour model, 2×106 CRC cells were suspended in 100μL PBS and then injected subcutaneously. Tumour volumes were measured every 3 or 4 days with a caliper and were calculated. For the drug treatment studies, daily doses of 20mg/kg atorvastatin, 20mg/kg SR1078 or the combination were administered via intraperitoneal (i.p.) injection. After the mice were euthanized, the tumours were excised and weighed. |
Dosage form | 20mg/kg; i.p. |
Applications | SR1078 significantly inhibited tumour growth in nude mice subcutaneously. |
References: | |
| Cas No. | 1246525-60-9 | SDF | |
| 别名 | SR 1078;SR-1078 | ||
| 化学名 | N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide | ||
| Canonical SMILES | C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O)C(F)(F)F | ||
| 分子式 | C17H10F9NO2 | 分子量 | 431.25 |
| 溶解度 | ≥ 43.2 mg/mL in DMSO, ≥ 43.4 mg/mL in EtOH | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3188 mL | 11.5942 mL | 23.1884 mL |
| 5 mM | 0.4638 mL | 2.3188 mL | 4.6377 mL |
| 10 mM | 0.2319 mL | 1.1594 mL | 2.3188 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet